Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYNCAR 001

Next Previous
Drug Profile

SYNCAR 001

Alternative Names: Orthogonal IL-2 receptor-modified CD-19 targeted CAR-T - Synthekine; STK 009/SYNCAR 001; STK-009 + SYNCAR-001; SYNCAR-001

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthekine
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Immunologic cytotoxicity; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological malignancies; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 09 Dec 2024 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Haematological malignancies released by Synthekine
  • 07 Dec 2024 Updated efficacy, adverse event and pharmacokinetic data from a phase I trial in Haematological malignancies presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)
  • 14 Nov 2024 Pharmacodynamics data from the preclinical trial in Autoimmune disorders presented at the ACR Convergence 2024 (ACR/ARP-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top